Research on how tools impact health, costs is 'inconclusive,' but clinicians say better-informed patients avoid unnecessary care, frustration
Jeff Cohen learned last May that a biopsy of his prostate came back positive for cancer. To treat the abnormal cells, his urologist offered a choice between radiation and surgery. But Cohen wanted a different option. Couldn't he choose instead to simply monitor the progress of the cancer through active surveillance?
That question—one formed by the 58-year-old's values and knowledge—sparked a discussion with his doctor that patient advocates, health policymakers and clinicians agree is too often missing from U.S. healthcare. That omission is a critical gap, they say, which leaves patients at risk for poorly informed decisions, unnecessary care and frustration that prompts some to abandon treatment.
It may also add to the nation's rising healthcare costs. The Institute of Medicine in 2010 put the annual price of unnecessary medical care at $210 billion. In addition, the underuse of appropriate treatment, particularly medications, because of poor patient decisions and other factors inflates the nation's healthcare tab.
Read the full story here: http://bit.ly/1aUVMja
Source: Modern Health
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More